Evaluating Dentsply Sirona: Insights From 8 Financial Analysts
During the last three months, 8 analysts shared their evaluations of Dentsply Sirona (NASDAQ:XRAY), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 4 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 3 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $34.12, with a high estimate of $41.00 and a low estimate of $28.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.93%.
Investigating Analyst Ratings: An Elaborate Study
The perception of Dentsply Sirona by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Elizabeth Anderson | Evercore ISI Group | Lowers | Outperform | $28.00 | $35.00 |
| Nathan Rich | Goldman Sachs | Lowers | Neutral | $30.00 | $34.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | Outperform | $35.00 | $40.00 |
| Michael Petusky | Barrington Research | Lowers | Outperform | $38.00 | $41.00 |
| Jason Bednar | Piper Sandler | Lowers | Neutral | $32.00 | $35.00 |
| Jeffrey Johnson | Baird | Lowers | Neutral | $33.00 | $35.00 |
| David Saxon | Needham | Lowers | Buy | $36.00 | $42.00 |
| Michael Petusky | Barrington Research | Maintains | Outperform | $41.00 | $41.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dentsply Sirona. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dentsply Sirona compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Dentsply Sirona's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dentsply Sirona's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Dentsply Sirona analyst ratings.
Get to Know Dentsply Sirona Better
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
Dentsply Sirona: A Financial Overview
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Decline in Revenue: Over the 3 months period, Dentsply Sirona faced challenges, resulting in a decline of approximately -2.56% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dentsply Sirona's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Dentsply Sirona's ROE excels beyond industry benchmarks, reaching 0.55%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.25%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.68, Dentsply Sirona adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.